Mirati Therapeutics Inc   (MRTX)
Other Ticker:  
Price: $58.7000 $-0.10 -0.170%
Day's High: $58.99 Week Perf: -0.47 %
Day's Low: $ 58.54 30 Day Perf: -0.14 %
Volume (M): 20,994 52 Wk High: $ 64.41
Volume (M$): $ 1,232,371 52 Wk Avg: $44.93
Open: $58.86 52 Wk Low: $27.30

 Market Capitalization (Millions $) 3,815
 Shares Outstanding (Millions) 65
 Employees -
 Revenues (TTM) (Millions $) 38
 Net Income (TTM) (Millions $) -726
 Cash Flow (TTM) (Millions $) -40
 Capital Exp. (TTM) (Millions $) 2

Mirati Therapeutics Inc
Mirati Therapeutics Inc. is a biopharmaceutical company that specializes in the development of targeted oncology therapeutics. The company focuses on developing drugs that target genetic and molecular alterations in cancer cells, with the aim of improving the outcomes for patients with cancer.

Mirati Therapeutics uses precision medicine approaches to identify and develop therapies for specific patient populations, particularly those with genetically-defined cancers. The company's pipeline includes both small molecule inhibitors and immuno-oncology treatments.

Mirati Therapeutics is known for its lead product candidate, adagrasib (MRTX849), which targets KRAS G12C mutations, a key driver of various types of cancer. The company is conducting clinical trials to evaluate the safety and efficacy of adagrasib in multiple cancer types.

In addition to adagrasib, Mirati Therapeutics is also working on other programs targeting specific genetic alterations, including codon 68 mutations in KRAS and exon 20 insertions in EGFR.

Overall, Mirati Therapeutics Inc. is dedicated to advancing precision oncology treatments and improving the lives of cancer patients by developing innovative therapies that target the underlying genetic and molecular drivers of cancer.

   Company Address: 3545 Cray Court, San Diego, 92121 CA
   Company Phone Number: 332-3410   Stock Exchange / Ticker: NASDAQ MRTX


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Mirati Therapeutics Inc

Mirati Therapeutics' Revenue Skyrockets by an Astonishing 201.97%: Third Quarter of 2023 Unleashes a Financial Triumph

Mirati Therapeutics Inc, a major player in the pharmaceutical preparations industry, unveiled its fiscal third-quarter results for 2023 with exciting revelations. Not only did the company witness a substantial reduction in losses per share and an improvement in earnings, but it also experienced an impressive boost in revenue. As we delve into the numbers, it becomes evident that Mirati Therapeutics Inc is on a trajectory of growth and is poised to make a significant impact moving forward.
Positive Earnings and Decreased Losses per Share:
In the fiscal third quarter of 2023, Mirati Therapeutics Inc achieved a significant milestone by reducing its losses per share to $-2.49, showcasing a remarkable improvement from the previous year's $-3.09 per share. This positive trend was also reflected in the improvement of earnings per share, which rose from $-3.04 in the previous quarter to a more favorable figure. These positive developments demonstrate the company's successful cost-control measures and strategic initiatives, positioning it for a stronger financial performance in the future.

Mirati Therapeutics Inc

Mirati Therapeutics Inc Shows Promise Despite Challenging Financials in Q2 2023

Mirati Therapeutics Inc, a major player in the pharmaceutical preparations industry, seems to be heading towards a bearish trajectory, plagued by a series of concerning financial indicators.
Looking at the financial time-frame closing in June 2023, Mirati Therapeutics reported a decreased loss per share of $-3.04, slightly better than the previous year's $-3.18. However, it's essential to note that even though there was improvement in the loss per share, the company is still incurring significant losses, which is concerning for its long-term viability.

Mirati Therapeutics Inc

Major Pharmaceutical Preparations Company Achieves Remarkable Success Throughout Recent Fiscal Period

Mirati Therapeutics Inc, a company in the healthcare sector, has reported a cumulative net loss of $-737 million in the 12-month period ending in the first quarter of 2023. This has resulted in a negative return on assets (ROA) of -61.07%. The company's ROA is lower than that of 299 other companies in the same sector, indicating that the company is not performing as well as its peers.
However, there is some positive news for Mirati Therapeutics Inc. It has improved its overall ROA ranking, moving up to 2053 from 4691 in the fourth quarter of 2022. In addition, for the January to March 2023 quarter, the company decreased its loss per share from $-3.40 to $-3.18 compared to the same period the year before. And, the earnings per share increased from $-3.25 to an unspecified higher amount from the preceding reporting season.


Mirati Therapeutics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com